Characteristic | No | In group (%) |
---|---|---|
Age, mean (range) | 61.5 (25–88) |  |
Age | ||
 > 60 years | 55/100 | 55 |
 ≤ 60 years | 45/100 | 45 |
Gender | ||
 Male | 57/100 | 57 |
 Female | 43/100 | 43 |
COO | ||
 GCB | 31/100 | 31 |
 Non-GCB | 69/100 | 69 |
PS | ||
 0–1 | 70/95 | 73.7 |
 2–5 | 25/95 | 26.3 |
Stage | ||
 I/II | 38/97 | 39.2 |
 III/IV | 59/97 | 60.8 |
IPI | ||
 0–1 | 45/96 | 46.9 |
 2–5 | 51/96 | 53.1 |
B-symptom | ||
 Yes | 32/98 | 32.7 |
 No | 66/98 | 67.3 |
Primary site | ||
 Nodal | 65/97 | 67 |
 Extranodal | 32/97 | 33 |
LDH > 220 IU/L | ||
 Yes | 39/68 | 57.4 |
 No | 29/68 | 42.6 |
Treatment | ||
 CHOP-based therapy | 77/90 | 85.6 |
 Other therapy | 13/90 | 14.4 |
Response to CHOP | ||
 CR + PR | 40/61 | 65.6 |
 SD + PD | 21/61 | 34.4 |